M
Michael Blind
Researcher at University of Bonn
Publications - 25
Citations - 1215
Michael Blind is an academic researcher from University of Bonn. The author has contributed to research in topics: Aptamer & Nucleic acid. The author has an hindex of 12, co-authored 25 publications receiving 1145 citations.
Papers
More filters
Journal ArticleDOI
Nucleic Acid AptamersFrom Selection in Vitro to Applications in Vivo
TL;DR: Using recently developed techniques, one can quickly obtain highly specific research reagents that act on defined intracellular targets in the context of the living cell and their use as in vivo modulators of cellular physiology is facilitated.
Journal ArticleDOI
Aptamer Selection Technology and Recent Advances.
Michael Blind,Michael Blank +1 more
TL;DR: This review highlights recent progress in the technical steps of a SELEX experiment with a focus on high-throughput next-generation sequencing and bioinformatics.
Journal ArticleDOI
Controlling small guanine-nucleotide-exchange factor function through cytoplasmic RNA intramers.
Günter Mayer,Michael Blind,Wolfgang Nagel,Thomas Böhm,Thomas Knorr,Catherine L. Jackson,Waldemar Kolanus,Michael Famulok +7 more
TL;DR: These highly specific cellular effects suggest that the ARF-GEF activity of cytohesin 1 plays an important role in cytoskeletal remodeling events of lymphoid cells.
Journal ArticleDOI
Intramers as promising new tools in functional proteomics
TL;DR: Recent developments and strategies for intramer-based technologies that have the potential to greatly facilitate characterisation of unknown protein functions in the context of their natural expression status in vivo are discussed.
Journal ArticleDOI
An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro
Günter Mayer,Bernhard Wulffen,Christian D. Huber,Jörg Brockmann,Birgit Flicke,Lars Neumann,Doris Hafenbradl,Bert Klebl,Martin J. Lohse,Cornelius Krasel,Michael Blind +10 more
TL;DR: The aptamer, C13, is two orders of magnitude more potent than the best GRK2 inhibitors described previously and shows high selectivity for the GRK family of protein kinases.